• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Melinta Up After Deal for Medicines' Infectious Disease Unit -- Biotech Movers

The New Haven, Conn.-based firm on Nov. 29 unveiled a deal to acquire The Medicines Co.'s infectious disease unit.
By ARMIE MARGARET LEE Nov 30, 2017 | 09:25 AM EST
Stocks quotes in this article: MLNT, MDCO, CLDX

Shares of Melinta Therapeutics Inc. (MLNT) rose 7.2% to $16.30 in premarket trading on Thursday, Nov. 30, a day after the New Haven, Conn.-based firm unveiled a deal to acquire  The Medicines Co.'s (MDCO) infectious disease unit.

The agreement, announced Wednesday morning, includes three marketed products: Vabomere (vaborbactam/meropenem), Orbactiv (oritavancin) and Minocin IV (minocycline). 

Terms of the deal include $270 million in upfront consideration and guaranteed payments, tiered royalty payments of 5% to 25% on global net sales of Vabomere, Orbactiv and Minocin IV, and the assumption by Melinta of all royalty, milestone and other payment obligations associated with those products.

Melinta shares closed at $15.20 on Wednesday, up 1.3%. Shares of Parsippany, N.J.-based Medicines finished Wednesday's trading session at $30.17, down 0.1%, and were up 5.3% to $31.76 ahead of the market open on Thursday.

For Melinta, the deal to buy Medicines' infectious disease business came after Melinta completed its merger with Cempra Inc. in early November.

Among the other stock movers was Celldex Therapeutics Inc. (CLDX) , up 4.4% to $3.10. The Hampton, N.J.-based firm said Thursday it has begun its open-label, Phase 1 study of CDX-1140 in patients that have advanced solid tumors.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Jim Cramer: We've Got a Boom ... and a Bust

Jim Cramer
Apr 15, 2021 3:36 PM EDT

Let's look at this impossible move on the market -- and why health care could be coming off life support.

TransMedics Group's Charts Are Pointed Lower

Bruce Kamich
Apr 15, 2021 9:30 AM EDT

These charts are not pretty.

A Subscriber Asks About 2 Biotech ETFs and Here's What We Found

Bruce Kamich
Apr 14, 2021 1:05 PM EDT

Traders and investors could go long IBB or XBI at current levels and look to add on strength.

Jim Cramer: Johnson & Johnson? Moderna and Pfizer Can Do the Job

Jim Cramer
Apr 13, 2021 2:35 PM EDT

You never want to be caught in a counter trend rally.

Charting NovoCure's Meteoric Stock Price Rise

Bruce Kamich
Apr 13, 2021 11:05 AM EDT

NVCR gapped sharply higher today, in one of the most impressive upside gaps we have seen in a long time. Check it out.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:42 PM EDT PAUL PRICE

    Wednesday on Real Money Pro

    Make this stock a 'part' of your portfolio.
  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • 11:18 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 5 Pillars of Exceptional Trading
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login